DE60129934T2 - Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie - Google Patents

Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie Download PDF

Info

Publication number
DE60129934T2
DE60129934T2 DE60129934T DE60129934T DE60129934T2 DE 60129934 T2 DE60129934 T2 DE 60129934T2 DE 60129934 T DE60129934 T DE 60129934T DE 60129934 T DE60129934 T DE 60129934T DE 60129934 T2 DE60129934 T2 DE 60129934T2
Authority
DE
Germany
Prior art keywords
sub
formula
hydrogen
tyrosine kinase
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129934T
Other languages
German (de)
English (en)
Other versions
DE60129934D1 (de
Inventor
Robert Charles Canterbury ATKINS
Steven James Blackrock Chadban
Mark Emmanuel Kew COOPER
Richard Ernest West St. Kilda Gilbert
Prudence Ann Canterbury Hill
Darren James Chirnside Village Kelly
David John Pearcedale Nikolic-Paterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NIKOLIC PATERSON DAVID JOHN
University of Melbourne
Southern Health
Novartis AG
Original Assignee
NIKOLIC PATERSON DAVID JOHN
University of Melbourne
Southern Health
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NIKOLIC PATERSON DAVID JOHN, University of Melbourne, Southern Health, Novartis AG filed Critical NIKOLIC PATERSON DAVID JOHN
Application granted granted Critical
Publication of DE60129934D1 publication Critical patent/DE60129934D1/de
Publication of DE60129934T2 publication Critical patent/DE60129934T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60129934T 2000-03-03 2001-03-01 Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie Expired - Lifetime DE60129934T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00810181 2000-03-03
EP00810181 2000-03-03
PCT/EP2001/002340 WO2001064200A2 (en) 2000-03-03 2001-03-01 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

Publications (2)

Publication Number Publication Date
DE60129934D1 DE60129934D1 (de) 2007-09-27
DE60129934T2 true DE60129934T2 (de) 2008-05-08

Family

ID=8174580

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129934T Expired - Lifetime DE60129934T2 (de) 2000-03-03 2001-03-01 Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie

Country Status (10)

Country Link
US (1) US7087608B2 (enExample)
EP (1) EP1259242B1 (enExample)
JP (1) JP2003525240A (enExample)
AT (1) ATE369860T1 (enExample)
AU (2) AU2001248324B2 (enExample)
CA (1) CA2401812C (enExample)
DE (1) DE60129934T2 (enExample)
ES (1) ES2291306T3 (enExample)
PT (1) PT1259242E (enExample)
WO (1) WO2001064200A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000186A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
CA2452368A1 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
DK1401415T3 (da) 2001-06-29 2006-10-16 Ab Science Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
ES2274993T3 (es) 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
ES2274075T3 (es) 2001-06-29 2007-05-16 Ab Science Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
JP2005504054A (ja) * 2001-08-25 2005-02-10 アラキス リミテッド 腎疾患の治療におけるアントラキノンの使用
US7332330B2 (en) * 2001-09-11 2008-02-19 Renamed Biologics, Inc. Device for maintaining vascularization near an implant
WO2003057165A2 (en) 2002-01-04 2003-07-17 The Rockefeller University COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
EP1509219A1 (en) * 2002-05-13 2005-03-02 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure
CA2494695C (en) 2002-08-02 2011-04-05 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
JP4776537B2 (ja) * 2003-05-27 2011-09-21 ロベルト・ペール・ヘーガークヴィスト 糖尿病処置のためのチロシンキナーゼ阻害剤の使用
ATE395052T1 (de) * 2003-08-15 2008-05-15 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
CN1905876B (zh) 2003-11-17 2010-06-09 诺瓦提斯公司 二肽基肽酶iv抑制剂的用途
US9073997B2 (en) 2007-02-02 2015-07-07 Vegenics Pty Limited Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
AU2009248923B2 (en) 2008-05-21 2015-01-29 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JP2602735B2 (ja) * 1989-09-27 1997-04-23 株式会社大塚製薬工場 抗活性酸素剤
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
JP3810020B2 (ja) 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5721277A (en) 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
CA2214393A1 (en) 1996-09-02 1998-03-02 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JPH10182644A (ja) * 1996-11-01 1998-07-07 Takeda Chem Ind Ltd 三環性化合物、その製造法及び剤
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
WO2000009098A2 (en) 1998-08-13 2000-02-24 Novartis Ag Method for treating ocular neovascular diseases

Also Published As

Publication number Publication date
US7087608B2 (en) 2006-08-08
AU2001248324B2 (en) 2005-09-15
HK1052864A1 (en) 2003-10-03
AU4832401A (en) 2001-09-12
US20030186977A1 (en) 2003-10-02
WO2001064200A2 (en) 2001-09-07
CA2401812A1 (en) 2001-09-07
CA2401812C (en) 2009-06-09
EP1259242B1 (en) 2007-08-15
JP2003525240A (ja) 2003-08-26
ATE369860T1 (de) 2007-09-15
EP1259242A2 (en) 2002-11-27
ES2291306T3 (es) 2008-03-01
PT1259242E (pt) 2007-11-15
DE60129934D1 (de) 2007-09-27
WO2001064200A3 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
DE60129934T2 (de) Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie
DE60014361T2 (de) Zyklische aminderivate und ihre verwendung
DE69937997T2 (de) Inhibitoren des transkriptionsfaktors nf-kappa b
DE69017302T2 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
DE69309094T2 (de) Hemmung der TNF - Bildung
DE60212836T2 (de) Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
DE69631134T2 (de) Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole
EP1176963B1 (de) Verwendung von dopamin-d 3-rezeptorantagonisten zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen
DE69900207T2 (de) Verwendung von 11-(3-dimethylaminopropyliden)-6,11-dihydrodibenz[b,e]oxepin-2-essigsäure und deren pharmazeutisch annehmbaren salzen zur herstellung eines medikaments zur behandlung nicht-allergisch-bedingten augenentzündungen und zur prevention der okularen neovaskularisation
KR102893133B1 (ko) 진행성 섬유화 간질성 폐 질환(pf-ild)의 치료를 위한 활성 제제들의 신규한 배합
DE60030338T2 (de) Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin und deren physiologisch akzeptablen Salzen
AU2001248324A1 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
DE60129518T2 (de) Verwendung von einem Vasopressin-Antagonisten wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension
DE60308337T2 (de) 4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyrimidin-3-yl)pyrimidin-2-ylamino)phenylbenzamid zur Behandlung von Ang II vermitteltern Erkrankungen
SK12312003A3 (sk) Použitie N-fenyl-2-pyridínamínových derivátov proti ochoreniam s účasťou žírnych buniek
DE69302646T2 (de) Benzimidazolverbindungen als Antibiotika gegen Campylobacter pylon
DE69933450T2 (de) Imidazolin-rezeptor-bindende verbindungen
DE60306896T2 (de) Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen
DE69917005T2 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
DE60130030T2 (de) Verfahren zur behandlung von glaukom
DE69003924T2 (de) Verhinderung von Entzugserscheinungen.
DE60307265T2 (de) Verwendung des metabolits von valsartan zur hemmung der thrombozytenaggregation
DE69029814T2 (de) Inhibitoren der dihydrofolatreduktase von pneumocystis carinii
DE60210783T2 (de) Nicht-peptidische ccr1-rezeptor-antagonisten zur behandlung der progressiven nierenfibrose
DE69501944T2 (de) Arzneimittel zur Vorbeugung oder Behandlung von chronischem Rheumatismus und Sepsis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 80336 MUENCHEN